Minimal residual disease (MRD) techniques are essential to identify the small clonal fraction within and outside the bone marrow. In the last years, evidence regarding their prognostic role for the evaluation of the depth of response of current treatment strategies has grown rapidly. Consequently, MRD was incorporated in an increasing number of clinical trials for multiple myeloma patients, also as primary endpoint, and even to guide therapeutic choices. A robust correlation between MRD negativity and survival was established. Yet, several issues regarding MRD evaluation remain to be addressed: from the optimal and more cost-effective techniques for its assessment and its harmonization worldwide to its use in clinical practice to its impact on treatment modulation. This review focuses on the available evidence supporting the use of MRD status for the management of multiple myeloma patients and on open issues that still need an answer.
Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
Mina R.First
;Bonello F.;Oliva S.Last
2021-01-01
Abstract
Minimal residual disease (MRD) techniques are essential to identify the small clonal fraction within and outside the bone marrow. In the last years, evidence regarding their prognostic role for the evaluation of the depth of response of current treatment strategies has grown rapidly. Consequently, MRD was incorporated in an increasing number of clinical trials for multiple myeloma patients, also as primary endpoint, and even to guide therapeutic choices. A robust correlation between MRD negativity and survival was established. Yet, several issues regarding MRD evaluation remain to be addressed: from the optimal and more cost-effective techniques for its assessment and its harmonization worldwide to its use in clinical practice to its impact on treatment modulation. This review focuses on the available evidence supporting the use of MRD status for the management of multiple myeloma patients and on open issues that still need an answer.
| File | Dimensione | Formato | |
|---|---|---|---|
|
[PUBLISHED Vsn.] Mina et al - 2021 - MRD in MM - Ready for Prime Time.pdf
Accesso riservato
Descrizione: [Restricted access - Published Vsn.] Mina R et al. Cancer J. 2021 May-Jun 01;27(3):247-255. doi: 10.1097/PPO.0000000000000519. PMID: 34549914. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. Available at / disponibile all’URL: https://journals.lww.com/journalppo/Abstract/2021/05000/Minimal_Residual_Disease_in_Multiple_Myeloma_.11.aspx --- https://doi.org/10.1097/ppo.0000000000000519
Tipo di file:
PDF EDITORIALE
Dimensione
422.98 kB
Formato
Adobe PDF
|
422.98 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
[Author Vsn] Mina et al - 2021 - Cancer J - MRD in MM - Prime time.pdf
Accesso riservato
Descrizione: [Restricted access - Pre-print Vsn.] Mina R. et al. Cancer J. 2021 May-Jun 01;27(3):247-255. doi: 10.1097/PPO.0000000000000519. PMID: 34549914. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. The publisher's version is available at: https://journals.lww.com/journalppo/Abstract/2021/05000/Minimal_Residual_Disease_in_Multiple_Myeloma_.11.aspx | https://doi.org/10.1097/ppo.0000000000000519. Open access removed upon acceptance for publication, as required by the publisher.
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
698.25 kB
Formato
Adobe PDF
|
698.25 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
